Management of Concurrent Bacterial Vaginosis, Vulvovaginal Candidiasis, and Chlamydia in Young Adults

Chlamydia Treatment

First‑line therapy: Azithromycin 1 g orally as a single, directly observed dose. (Strong CDC recommendation) 1
Efficacy: Azithromycin and doxycycline achieve comparable cure rates of 97‑98 %; azithromycin is preferred for its single‑dose adherence advantage. (Strong CDC recommendation) 1
Alternative regimen: Doxycycline 100 mg orally twice daily for 7 days may be used when cost is a concern. (CDC recommendation) 1
Sexual abstinence: Patients should refrain from intercourse for 7 days after treatment and until all partners have been treated to avoid reinfection. (CDC recommendation) 1
Partner management: All sexual partners within the preceding 60 days must be evaluated and treated. (CDC recommendation) 1
Test‑of‑cure: Not required unless symptoms persist or reinfection is suspected. (CDC recommendation) 1
Retesting: Recommend chlamydia retesting at 3 months because of high reinfection rates in young women. (CDC recommendation) 1

First‑line regimen: Metronidazole 500 mg orally twice daily for 7 days, yielding ~95 % cure versus 84 % with a single‑dose regimen. (Strong CDC recommendation) 4
Alternative regimens:
- Metronidazole gel 0.75 % intravaginally twice daily for 5 days.
- Clindamycin cream 2 % intravaginally at bedtime for 7 days. (CDC recommendation) 4
Alcohol avoidance: Patients should avoid alcohol during metronidazole therapy and for 24 hours after completion to prevent disulfiram‑like reactions. (CDC recommendation) 4
Partner treatment: Not recommended, as it does not reduce recurrence rates. (CDC recommendation) 7
Follow‑up: Unnecessary if symptoms resolve. (CDC recommendation) 7

First‑line therapy: Fluconazole 150 mg orally as a single dose. (Strong CDC/Clinical Infectious Diseases recommendation) 3
Alternative therapy: Any topical azole (e.g., clotrimazole 1 % cream 5 g intravaginally for 7‑14 days, miconazole 2 % cream 5 g for 7 days, or terconazole 0.4 % cream 5 g for 7 days). (CDC recommendation) 3
Convenience vs. efficacy: Oral fluconazole offers convenience; efficacy is comparable to topical agents. (CDC recommendation) 3
Test‑of‑cure: Not required if symptoms resolve. (CDC recommendation) 3

Concurrent treatment: All three infections can be treated at the same time; no known drug‑drug contraindications. (CDC/Clinical Infectious Diseases recommendation) [1][3]
Administration: Deliver azithromycin as directly observed therapy on site to ensure compliance. (CDC recommendation) 1
Medication dispensing: Provide all prescribed medications on site when feasible. (CDC recommendation) 1
Drug interaction: The metronidazole regimen for BV does not interfere with azithromycin or fluconazole therapy. (CDC recommendation) 4

Partner treatment limited to chlamydia: Do not treat partners for BV or VVC; only chlamydia contacts require therapy. (CDC recommendation) [7][1]
Retesting for chlamydia: Perform a repeat test at 3 months regardless of treatment completion. (CDC recommendation) 1
Return visit: Needed only if symptoms of any condition persist. (CDC recommendation) 7
STI screening: Offer screening for HIV, syphilis, and hepatitis B in patients diagnosed with chlamydia. (CDC recommendation) 2
Counseling: Advise barrier contraception use and partner notification. (CDC recommendation) 1
Avoid duplicate routes: Do not combine oral metronidazole with metronidazole gel; select one route of administration. (CDC recommendation) 4
Pregnancy precaution: Verify pregnancy status before prescribing doxycycline, as it is contraindicated in possible pregnancy. (CDC recommendation) 8